Kura Oncology Inc (KURA)
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (83%) **Content type:** Clinical